

CURRICULUM VITAE AND BIBLIOGRAPHIC OUTLINE
Baylor College of Medicine-VAMC Sleep Research Program
Veterans Affairs Medical Center- 111i
2002 Holcombe Blvd
Houston, TX 77030
713-794-7318 / email amirs@bcm.edu

I. General Biographical Information

A. Personal Information:

- 1. Name:** Amir Sharafkhaneh, M.D., Ph.D.
- 2. Date of Birth** March 2, 1964

B. Education:

1) Medical School:

1982- 1988 Tehran University of Medical Sciences
Tehran, Iran (1982-1990)

2) Post Graduate Training:

2002-2008 Baylor College of Medicine, Clinical Scientist Training Program
Ph.D. Program

1997-2000 Baylor College Of Medicine Pulmonary, Critical Care and Sleep
Medicine Fellowship

1994-1997 Long Island College Hospital, Internal Medicine Residency

1988-1990 Tehran University Of Medical Sciences, Internship

C. Academic Appointments: title and dates of appointment

1. Faculty position(s) at BCM:

2014-Present Professor (tenure track) of Medicine, Baylor College of Medicine

2008-2014 Associate Professor of Medicine, Baylor College of Medicine

2000-2008 Assistant Professor of Medicine, Baylor College of Medicine

2. Previous faculty position(s) at other institutions: None

3. Faculty appointment(s) at other institutions while at BCM:

2005-2010 Adjunct Assistant Professor of Medicine, MD Anderson Cancer Center

D. Other advanced training/experience: (with locations, dates and sources of support)

1. Formal Sabbatical leave: None

2. Other specialized training following academic appointment:

1999-2000 Advance Pulmonary Physiology (Mentor: Dr. J. Rodarte)
Baylor College of Medicine

E. Other information

1. Awards & Honors:

2014 Fulbright and Jaworski Award for Educational Leadership, Baylor College of Medicine
2014 Office of Rural Health, VHA. Three years funding (\$194,000 annual support) to develop telemedicine program to manage insomnia.
2012 Office of Rural Health, VHA. Three years funding (\$200,000 annual support) to develop telemedicine program to diagnose and manage sleep disordered breathing.
2005 Fulbright and Jaworski Award for Faculty Excellence in Teaching and Evaluation, Baylor College of Medicine
2002 Joe Rodarte Young Investigator Award, Baylor College of Medicine
1994 Intern-of-The-Year in Internal Medicine, Long Island College Hospital
1988 Top 10% Iranian Internship Entrance Exam
Tehran University of Medical Sciences
1982 Top 1% Iranian National University Entry Exam
Tehran, Iran

2. Board Eligibility/Certification

2010 Recertification in Critical Care Medicine, ABIM
2009 Recertification in Pulmonary Diseases, ABIM
2007 Recertification in Internal Medicine, ABIM
2007 Sleep Medicine, ABIM
2001 American Board of Sleep Medicine (ABSM)
2000 Critical Care Medicine, ABIM
1999 Pulmonary Diseases, ABIM
1997 Internal Medicine, ABIM

4. Other Certification

2002 Baylor College of Medicine, Certificate of Added Qualification in Clinical Research
1994 Certificate of the Educational Commission for Foreign Medical Graduates (ECFMG)

5. Medical Licensure

1999 Texas- Active, K7100

6. Other non-academic positions: (with locations, titles, dates of employment)

2007-Present Program Director, Sleep Medicine Fellowship Program, Baylor College of Medicine
2007-Present Sleep Medicine Fellowship Site Director, Sleep Disorders & Research Center, Michael DeBakey VA Medical Center

II. RESEARCH INFORMATION

A. Research Support: for each Project identify:

1) Active

Title: Genetic Epidemiology of Chronic Obstructive Pulmonary Disease: The COPD GENE Study

Funding Agency: NIH

Role: Site PI

Date of Funding: 11/01/2007 – 10/30/2017

Annual Direct Cost: \$50,000

Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY OF LONG-TERM USE OF PERFORMIST® (FORMOTEROL FUMARATE) INHALATION SOLUTION IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).

Funding Agency: DEY Pharma

Role: Site PI

Date of Funding: 03/01/2012 – 03/30/2015

Annual Direct Cost: \$60,000

Title: A SAFETY AND EFFICACY STUDY OF INHALED FLUTICASONE ROPIONATE/SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPRIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH ASTHMA

Funding Agency: GSK

Role: Site PI

Date of Funding: 03/01/2012 – 03/30/2014

Annual Direct Cost: \$50,000

Title: A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 MICROGRAMS ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID (LABA/ICS) (FOREST RESEARCH INSTITUTE)

Funding Agency: Forest Research Institute

Role: Site PI

Date of Funding: 01/01/2012 – 01/30/2014

Annual Direct Cost: \$80,000

Title: AN OBSERVATIONAL STUDY TO ASSESS RESPIRATORY SYNCYTIAL VIRUS (RSV)-ASSOCIATED ILLNESS IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR CONGESTIVE HEART FAILURE (CHF)

Funding Agency: ASTRA ZENECA

Role: Site PI

Date of Funding: 01/01/2012 – 06/30/2015

Annual Direct Cost: \$50,000

Title: A CLINICAL OUTCOMES STUDY TO COMPARE THE EFFECT OF FLUTICASONE FUROATE/VILANTEROL INHALATION POWDER 100/25MCG WITH PLACEBO ON SURVIVAL IN SUBJECTS WITH MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND A HISTORY OF OR AT INCREASED RISK FOR CARDIOVASCULAR DISEASE.

Funding Agency: GSK

Role: Site PI

Date of Funding: 03/01/2012 – 03/30/2015

Annual Direct Cost: \$70,000

Title: TO STUDY THE CIRCADIAN SLEEP PATTERN AND ITS CORRELATION WITH SUBJECTIVE SLEEP COMPLAINTS IN VETERANS WITH PARKINSON'S DISEASE

Funding Agency: Department of Veterans Affairs

Role: Co-PI (PI is Dr. Aliya Iftikhar Sarwar)

Date of Funding: 06/01/2010 – 03/30/2014

Annual Direct Cost: \$125,000

Title: THE EXAMINATION OF HIV-ASSOCIATED LUNG EMPHYSEMA (EXHALE)

Funding Agency: NIH

Role: Site Co-PI (site PI: Dr. Maria Rodriguez-Baradas)

Date of Funding: 7/01/2011 – 6/30/2013

Annual Direct Cost: \$100,000

2) Completed

Title: An Eight-Week, Multicenter, Double-Blind, Randomized, Parallel Group Study Of Fluticasone Propionate/Salmeterol Diskus Combination Product (Fsc) 250/50 Micro Grams Twice Daily Plus Tiotropium 18 Micro Grams Daily Versus Placebo Diskus Twice Daily Plus Tiotropium 18 Micro Grams Daily On Exercise Time And Physiological Parameters In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Funding Agency: GSK

Role: Site PI

Date of Funding: 08/01/2010 – 06/30/2012

Annual Direct Cost: \$60,000

Title: A 52-WEEK EFFICACY AND SAFETY STUDY TO COMPARE THE EFFECT OF THREE DOSAGE STRENGTHS OF FLUTICASONE FUROATE/GW642444 INHALATION POWDER WITH GW642444 ON THE ANNUAL RATE OF EXACERBATIONS IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Funding Agency: GSK

Role: Site PI

Date of Funding: 06/01/2010 – 03/30/2012

Annual Direct Cost: \$65,000

Title: A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GSK573719/GW642444 INHALATION POWDER AND THE INDIVIDUAL COMPONENTS DELIVERED ONCE-DAILY VIA A NOVEL DRY POWDER INHALER IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (GSK - DB2113373).

Funding Agency: GSK

Role: Site PI
Date of Funding: 01/01/2011 – 04/30/2012
Annual Direct Cost: \$35,000

Title: A Randomized, Double-Blind, Parallel Group, Multicenter Study Of The Effects Of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Bid (Advair Diskus™) In Comparison To Salmeterol 50mcg Bid (Serevent Diskus™) On The Rate Of Exacerbations Of Chronic Obstructive Pulmonary Disease (COPD) Following Hospitalization

Funding Agency: GSK
Role: Site PI
Date of Funding: 08/01/2010 – 06/30/2011
Annual Direct Cost: \$60,000

Title: A Large Simple Safety Study Of Arformoterol Tartrate Inhalation Solution In Subjects With Chronic Obstructive Pulmonary Disease

Funding Agency: Sepracore
Role: Site PI
Date of Funding: 08/01/2010 – 06/30/2011
Annual Direct Cost: \$60,000

Title: Autophagy in Alveolar Macrophages

Funding Agency: Chest-Alpha 1 Foundation
Role: Site PI
Date of Funding: 07/01/2008 – 06/30/2009
Annual Direct Cost: \$25,000

Title: Bronchitis and Emphysema Advice and Training to Reduce Hospitalization

Funding Agency: Veterans Administration
Role: Site PI
Date of Funding: 11/01/2006 – 10/30/2011
Annual Direct Cost: \$78,000

Title: Health Care Utilization in Patients with COPD.

Funding Agency: GlaxoSmithKline
Role: PI
Date of Funding: 02/01/2006 – 03/31/2008
Annual Direct Cost: \$50,000

Title: The Role of Intrinsic Efficacy of Beta-Adrenergic Agonists in Determining Their Bronchodilator Responsiveness in Adults with Acute Severe Asthma

Funding Agency: NIH K-23
Role: consultant
02/01/2006 – 01/31/2008
Annual Direct Cost: \$150,000

Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Assessing The Rate Of Decline Of Lung Function With Tiotropium 18 Mcg Inhalation Capsule Once Daily In Patients With Chronic Obstructive Pulmonary Disease (COPD).

Funding Agency: Bohringer-Ingelheim
Role: Site PI
Date of Funding: 12/01/2003 – 11/30/2008
Annual Direct Cost: \$50,000

Title: A double-blind, randomized, placebo controlled study to investigate chronic intermittent "pulse" therapy of moxifloxacin as a prevention of acute exacerbation in out-patients with chronic bronchitis

Funding Agency: Bayer Pharmaceutical
Role: Site PI
Date of Funding: 12/01/2004 – 06/30/2008
Annual Direct Cost: \$50,000

Title: A 12-month double-blind, double-dummy, randomized, parallel group, multi-center efficacy and safety study of symbicort Pmdi 2 x 160/4.5 micrograms bid and 2 x 80/4.5 micrograms bid compared to formoterol turbo haler 2 x 4.5 micrograms bid and placebo in patients with COPD (sun study)

Funding Agency : Asterozenica
Role: Site Pi
Date of Funding : 06/01/2005 – 06/30/2008
Annual Direct Cost: \$50,000

Title: A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study Of Symbicort Pmdi 2 X 160/4.5 micrograms & 80/4.5 micrograms Bid Compared To Formoterol turbo haler, Budesonide Pmdi (& The Combination) & Placebo In COPD Patients (Shine Study) Center# 509, E Code

Funding Agency : Asterozenica
Role: Site PI
Date of Funding : 06/01/2005 – 06/30/2007
Annual Direct Cost: \$50,000

Title: A Double-Blind, Randomized, Parallel-Group, Multicenter Clinical Study To Compare The Efficacy And Tolerability Of Tiotropium Bromide Alone Vs. The Co-Administration of Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD- Po4272

Funding Agency: Schering-Plough Pharmaceutical
Role: Site PI
Date of Funding: 06/01/2005 – 06/30/2007
Annual Direct Cost: \$50,000

Title: Effect of Curcumin on Lung Inflammation

Funding Agency: MD Anderson Cancer Center
Role: Pi
Date of Funding: 9/01/2005 – 06/30/2007
Annual Direct Cost: \$40,000

Title: A Multicenter 3 Year Longitudinal Study to Identify Novel Endpoints and Compare These with Forced Expiratory Volume In 1 Second (FEV1) for Their Ability to Measure And Predict COPD Severity and Its Progression Over Time.

Funding Agency: Glaxosmithklein
Role: Site PI

Funding Date: 06/01/2006 – 06/30/2010
Annual Direct Cost: \$50,000

Title: Aura - Effect of Roflumilast in Exacerbation Rate In Patients With COPD. A 52 Weeks, Double-Blind Study with 500mg Roflumilast Once Daily Versus Placebo (

Funding Agency: Altana Pharmaceutical

Role: Site Pi

Funding Date: 06/01/2005 – 06/30/2007

Annual Direct Cost: \$50,000

Title: A Randomized Double-Blind, Double-Dummy, Parallel Group Trial Comparing 12 Weeks Treatment with Tiotropium Inhalation Capsules 18mcg Via The Handihaler Once Daily to Combivent Inhalation Aerosol 2 Actuations qid in COPD Patients Currently Prescribed Combivent Inhalation Aerosol

Funding Agency: Boehringer-Ingelheim

Role: Site PI

Funding Date: 06/01/2006 – 6/30/2008

Annual Direct Cost: \$60,000

Title: A Double-Blind, Placebo-Controlled Efficacy (As Assessed By Post-Bronchodilator Fev1) And Safety Study Of 5 Mg Ro3300074 Once-Daily For 2 Years In Subjects With Smoking-Related, Moderate-To-Severe COPD With Emphysema Receiving Concurrent Optimal COPD Drug Therapy.

Funding Agency : Roche

Role: Site PI

Date of Funding : 04/01/2007 – 03/31/2010

Annual Direct Cost: \$100,000

Title: A Phase IIIb, 12-Month, Double-Blind, Double-Dummy, Randomized, Parallel-Group, Multicentre Exacerbation Study of Symbicort® Pmdi 160/4.5 Micrograms X 2 Actuations Twice-Daily and 80/4.5 Micrograms X 2 Actuations Twice-Daily Compared to Formoterol Tbh 4.5 Micrograms X 2 Inhalations Twice-Daily In COPD Subjects

Funding Agency : Asterozenica

Role: Site Pi

Date of Funding : 04/01/2007 – 12/30/2008

Annual Direct Cost: \$60,000

Title: A 26-Week Treatment, Multicenter, Randomized, Double-blind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of Two Doses Of Indacaterol (Selected From 75, 150, 300 & 600 Micro Grams O.D.) In Patients with Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 Micro Grams B.I.D) And Open Label Tiotropium (18 Micro Grams O.D.) As Active Controls

Funding Agency : Novartis

Role: Site PI

Date of Funding : 04/01/2007 – 12/30/2009

Annual Direct Cost: \$60,000

Title: A Randomized, Multiple-Dose, Double-Blind, Crossover Study to Compare The Efficacy and Safety Of 200 mcg And 400 mcg of BEA 2180 to Tiotropium 5 mcg and Placebo When Each Is Delivered by The Respimat Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Funding Agency: Boehringer-Ingelheim

Role: Site PI

Date of Funding: 04/01/2005 – 06/30/2007

Annual Direct Cost: \$60,000

Title: A Prospective Observational Study for The Psychometric Validation Of A Patient-Reported Questionnaire In Acute Exacerbation Of Chronic Obstructive Pulmonary Disease (AECOPD)

Funding Agency: GlaxoSmithKline

Role: Site PI

Date of Funding: 01/01/2007 – 06/30/2007

Annual Direct Cost: \$20,000

Title: Focus Groups to Assess Fatigue in COPD

Funding Agency: GlaxoSmithKlein

Role: Site PI

Date of Funding: 04/01/2007 – 06/30/2007

Annual Direct Cost: \$8,000

Title: A Retrospective Collection of Vital Status And Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely from Either of Two One-Year Trials (205.254, 205.255) of Tiotropium Inhalation Solution Delivered by The Respimat® Inhaler

Funding Agency: Boehringer-Ingelheim

Role: Site PI

Date of Funding: 04/01/2007 – 06/30/2007

Annual Direct Cost: \$60,000

Title: Effect of Cardiac Overdrive Pacing On Obstructive Sleep Apnea

Funding Agency: NIH

Role: PI

Date of Funding: 7/01/2003-6/30/2005

Annual Direct Cost: 175,000

Title: Effects of Lung Volume Reduction Surgery In The Treatment Of Severe Emphysema

Funding Agency: VA Merit Review

Role: Co-PI

Date of Funding: 3/01/1997-3/01/2002

B. National Scientific Participation: (include dates and titles)

1. Membership and Fellowship in Professional Societies

Member, American Academy of Sleep Medicine (AASM)

Member, American Thoracic Society (ATS)

Fellow, American College of Chest Physicians (ACCP)

Member, World Association of Sleep Professional (WASM)

2. Professional Leadership Positions

Co-Chair, Veterans Administration Field Advisory Board for Chronic Obstructive Pulmonary Disease Guideline development (2013-Present)
Member, Veterans Administration Field Advisory Board for Chronic Obstructive Pulmonary Disease Guideline development
Member, Veterans Administration Field Advisory Board for Positive Airway Pressure
Member, Veterans Administration Field Advisory Board for Supplemental Home O2
Co-Chair, VA Interest Group, American Thoracic Society Annual International Meeting
Member, Telehealth Group, Michael E. DeBakey VA Medical Center
Member, COPD DMP Development, Veterans Administration
Member, Clinical Problem Web Committee, American Thoracic Society
Steering Committee Members, Pulmonary Physiology, Function, and Rehabilitation NetWork, American College of Chest Physicians
Member, Sleep Medicine Fellowship Committee, Masieh Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3. Invited Lectures and Presentations (Local, National, and International)

(See Lecture Section)

4. Review Panel

1. American Journal of Respiratory and Critical Care Medicine
2. Chest
3. Cochrane Review
4. Respiratory Medicine
5. International Journal of COPD
6. Thorax
7. Journal of Affective Disorders
8. Sleep
9. Respiration
10. Journal of Thoracic Disease
11. Current Medical Research and Opinion
12. Therapeutic Advances in Respiratory Disease
13. ISRN Pulmonology
14. European Journal of Psychiatry
15. Respiratory Care
16. Journal of Internal Medicine
17. Expert Review of Respiratory Medicine
18. British Medical Journal Open

5. Editorial Board

1. Journal of Internal Medicine

C. Publications

1. Full Papers:

a. Published in referred journals

1. **Sharafkhaneh A.**, Hanania NA., Colice GL., Donohue JF., Altan A., Kurlander JL, Rodriguez-Roisin R., Altman PR., A SIMPLE RULE TO IDENTIFY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO MAY NEED TREATMENT REEVALUATION, Respiratory Medicine (In Press)

2. Crothers K., McGinnis K., Kleerup E., Wongtrakool C., Hoo GS., Kim J., **Sharafkhaneh A.**, Haung L., Luo Z., Thompson B., Diaz P., Kirk GD., Row W., Detels R., Kingsley L., Morris A. HIV infection is associated with reduced pulmonary diffusing capacity. *J Acquir Immune Defic Syndr*, 2013;64(3):271-8
3. **Sharafkhaneh A**, Wolf RA, Goodnight S, Hanania NA, Make BJ, Tashkin DP. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. *COPD*. 2013 Aug;10(4):482-92.
4. **Sharafkhaneh A**, Majid H, Gross NJ. Safety and tolerability of inhalational anticholinergics in COPD. *Drug Healthc Patient Saf*. 2013;5:49-55.
5. Benzo R, Siemion W, Novotny P, Sternberg A, Kaplan RM, Ries A, Wise R, Martinez F, Utz J, Sciruba F; National Emphysema Treatment Trial Research Group (**Sharafkhaneh A**). Factors to inform clinicians about the end of life in severe chronic obstructive pulmonary disease. *J Pain Symptom Manage*. 2013 Oct;46(4):491-499
6. **Sharafkhaneh A**, J. Melendez, F. Akhtar, C. Lan. Cardiorespiratory causes of Fatigue. *Sleep Med Clin* 2013
7. **Sharafkhaneh A**, J. Melendez, F. Akhtar, M. Hirshkowitz. Medical Management of Fatigue, *Sleep Med Clin* 2013
8. **Sharafkhaneh A**, H. Majid and N.J.Gross. Safety and Tolerability of Inhalational Anticholinergics in COPD. *Drug, Healthcare and Patient Safety*, 2013;5:49-55
9. Al-shair K, Muellerova H, Yorke J, Rennard SI, Wouters EF, Hanania NA, **Sharafkhaneh A**, Vestbo J; ECLIPSE investigators. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. *Health Qual Life Outcomes*. 2012. 23;10:100.
10. Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, **Sharafkhaneh A**, Lotan R, Wistuba II. G-protein coupled receptor family C, group 5, member A (GPC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. *J Thorac Oncol*. 2012 Dec;7(12):1747-54.
11. Fan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG, Leatherman S, Thwin SS, Huang GD, Robbins R, Sriram PS, **Sharafkhaneh A**, Mador MJ, Sarosi G, Panos RJ, Rastogi P, Wagner TH, Mazzuca SA, Shannon C, Colling C, Liang MH, Stoller JK, Fiore L, Niewoehner DE. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalization: a randomized controlled trial. *Annals of Internal Medicine*, 2012;156 (10): 673-83.
12. **Sharafkhaneh A**, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. *Respir Med*. 2012;106(2):257-68.
13. Hirshkowitz M, **Sharafkhaneh A**. Normal sleep-recording and scoring techniques. *Handb Clin Neurol* 2011; 98: 29-43.

14. Hesselbacher S, Mattawal A, **Hirshkowitz M**, Sharafkhaneh A. Classification, technical specifications, and types of home sleep testing devices for sleep disordered breathing. *Sleep Med Clin* 2011.
15. Hirshkowitz M, **Sharafkhaneh A**. Comparison of portable monitoring with laboratory polysomnography for diagnosing sleep-related breathing disorders: scoring and interpretation. *Sleep Med Clin* 2011.
16. Garcia J, Sharafkhaneh H, Hirshkowitz M, Elkhatib R Red Utmb Edu, **Sharafkhaneh A**. Weight and Metabolic Effects of CPAP in Obstructive Sleep Apnea patients with obesity. *Respir Res*. 2011;12(1):80.
17. McCurdy MR, **Sharafkhaneh A**, Abdel-Monem H, Rojo J, Tittel FK. Exhaled nitric oxide parameters and functional capacity in chronic obstructive pulmonary disease. *J Breath Res*. 2011;5(1):016003.
18. Kim DK, Hersh CP, Washko GR, Hokanson JE, Lynch DA, Newell JD, Murphy JR, Crapo JD, Silverman EK; COPD Gene Investigators. Epidemiology, radiology, and genetics of nicotine dependence in COPD. *Respir Res*. 2011;12:9.
19. Hanania NA*, **Sharafkhaneh A***, Celli B, Decramer M, Lystig T, Kesten S, Tashkin D. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. *Respir Res*. 2011;12:6.(* Co-Primary Authors)
20. Hirshkowitz M, **Sharafkhaneh A**. Sleep and genitourinary systems: physiology and disorders. *Handb Clin Neurol*. 2011;98:355-62.
21. Hirshkowitz M, **Sharafkhaneh A**. Normal sleep-recording and scoring techniques. *Handb Clin Neurol*. 2011;98:29-43.
22. **Sharafkhaneh A**, Mattawal AS, Abraham VM, Dronavalli G, Hanania NA. Budesonide/formoterol combination in COPD: a US perspective. *Int J Chron Obstruct Pulmon Dis*. 2010;5:357-66.
23. Hanania NA, Sharma G, **Sharafkhaneh A**. COPD in the elderly patient. *Semin Respir Crit Care Med*. 2010;31(5):596-606.
24. Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, Renard SI, **Sharafkhaneh A**; on behalf of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of Depression in the ECLIPSE Chronic Obstructive Pulmonary Disease Cohort. *Am J Respir Crit Care Med*. 2011;183(5):604-611.
25. **Sharafkhaneh A**, Petersen NJ, Yu HJ, Dalal AA, Johnson ML, Hanania NA. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. *Int J Chron Obstruct Pulmon Dis*. 2010 May 6;5:125-32.
26. Kumar S, **Sharafkhaneh A**, Edmonds J, Schultz R, Hopkins B. Treatment of VNS-induced laryngospasm with botulinum toxin. *Neurology*. 2009;73(21):1808-10.
27. **Sharafkhaneh A**, Jayaraman G, Kaleekal T, Sharafkhaneh H, Hirshkowitz M. Sleep disorders and their management in patients with COPD. *Ther Adv Respir Dis*. 2009

;3(6):309-18. Review.

28. Niewoehner DE, Lapidus R, Cote C, **Sharafkhaneh A**, Plautz M, Johnson P, Kesten S. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. *Pulm Pharmacol Ther.* 2009;22(6):587-92.
29. Bailey WC, Scirba FC, Hanania NA, Donohue JF, Ferguson GT, Zibrak JD, **Sharafkhaneh A**, Marcus P, Rosa K, Piau EC, Martinez FJ. Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). *Prim Care Respir J.* 2009;18(3):198-207.
30. Jayaraman G, **Sharafkhaneh H**, Hirshkowitz M, Sharafkhaneh A. Pharmacotherapy of obstructive sleep apnea. *Ther Adv Respir Dis.* 2008 Dec;2(6):375-86. Review. PubMed PMID: 19124383.
31. Cote C, Pearle JL, **Sharafkhaneh A**, Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. *Pulm Pharmacol Ther.* 2009 Feb;22(1):44-9.
32. **Sharafkhaneh A**, Hanania NA, Kim V. Pathogenesis of emphysema: from the bench to the bedside. *Proc Am Thorac Soc.* 2008 May 1;5(4):475-7. Review.
33. **Sharafkhaneh A**, Falk JA, Minai OA, Lipson DA. Overview of the perioperative management of lung volume reduction surgery patients. *Proc Am Thorac Soc.* 2008 May 1;5(4):438-41. Review.
34. Kim V and **Sharafkhaneh A**. Oxygen Therapy in Chronic Obstructive Pulmonary Disease. *Proc Am Thorac Soc.* 2008 May 1;5(4):513-8.
35. Fessler H, Scharf S, Ingenito E, McKenna R, **Sharafkhaneh A**. Physiologic Basis for Improvements With LVRS. *Proc Am Thorac Soc.* 2008 May 1;5(4):416-20.
36. Criner GJ, **Sharafkhaneh A**, Player R, Conoscenti CS, Johnson P, Keyser MT, Cassino C. Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. *COPD.* 2008 Feb;5(1):35-41.
37. Kunik ME, Veazey C, Cully JA, Soucek J, Graham DP, Hopko D, Carter R, **Sharafkhaneh A**, Goepfert EJ, Wray N, Stanley MA. COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: a randomized controlled trial. *Psychol Med.* 2008;38(3):385-96.
38. Washko GR, Scirba F, Criner G, Mohensifar Z, **Sharafkhaneh A**, Hoffman E. CT based quantification of emphysema and correlation to lung function and mechanics" In-press in *COPD: Journal of Chronic Obstructive Pulmonary Disease.* COPD. 2008;5(3):177-86.
39. Hanania NA, **Sharafkhaneh A**. Update on the pharmacologic therapy for chronic obstructive pulmonary disease. *Clin Chest Med.* 2007;28(3):589-607.

40. Xu Y, Jagannath C, Liu XD, **Sharafkhaneh A**, Kolodziejska KE, Eissa NT. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. *Immunity*. 2007;27(1):135-44.
41. Hogg JC, Chu FS, Tan WC, Sin DD, Patel SA, Pare PD, Martinez FJ, Rogers RM, Make BJ, Criner GJ, Cherniack RM, **Sharafkhaneh A**, Luketich JD, Coxson HO, Elliott WM, Sciruba FC. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. *Am J Respir Crit Care Med*. 2007;176(5):454-9.
42. **Sharafkhaneh A**, Babb TG, Officer TM, Hanania NA, Sharafkhaneh H, Boriek AM. The confounding effects of thoracic gas compression on measurement of acute bronchodilator response. *American Journal of Respiratory and Critical Care Medicine* 2007; 175(4):330-5.
43. Niewoehner DE, Likhnygina Y, Rice K, Kuschner WG, **Sharafkhaneh A**, Sarosi GA, Krumpke P, Pieper K, Kesten S. Risk indexes for exacerbations and hospitalizations due to COPD. *Chest* 2007; 131(1): 20-8.
44. **Sharafkhaneh A**, Velamuri S, Badmaev V, Lan C, Hanania NA. The Potential Role of Natural Agents in Treatment of Airway Inflammation. *Ther Adv Respir Dis*. 2007 ;1(2):105-20. Review.
45. Hanania NA, Moore RH, Zimmerman JL, Miller CT, Bag R, **Sharafkhaneh A**, Dickey BF. The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. *Respiratory Medicine* 2007; 101(5):1007-14.
46. **Sharafkhaneh A**, Sharafkhaneh H, Bredikus A, Guilleminault C, Hirshkowitz M. Effect of atrial overdrive pacing on obstructive sleep apnea in patients with systolic heart failure. *Sleep Med*. 2007; 8(1):31-6
47. **Sharafkhaneh A**, Goodnight-White S, Sharafkhaneh H, Hirshkowitz M, Young T. Epidemiology of Sleep Related Breathing Disorders: Comparisons with the Veterans Health Administration Databases. *Sleep Medicine Clinics* 2006; 1(4):443-448.
48. Cully JA, Graham DP, Stanley MA, Ferguson CJ, **Sharafkhaneh A**, Soucek J, Kunik ME. Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. *Psychosomatics*. 2006 Jul-Aug;47(4):312-9.
49. Hirshkowitz M, **Sharafkhaneh A**, Kryger M. Clinical and Laboratory Assessment of Sleep-Related Breathing Disorders. *Sleep Medicine Clinics* 2006; 1(4):449-460.
50. Littner M, Hirshkowitz M, **Sharafkhaneh A**, Goodnight-White S. Non laboratory Assessment of Sleep-Related Breathing Disorders. *Sleep Medicine Clinics* 2006; 1(4):461-464
51. Sharafkhaneh H, **Sharafkhaneh A**. Sleep-Related Breathing Disorders and Quality of Life. *Sleep Medicine Clinics* 2006; 1(4):519-527

52. Sciruba FC, Martinez FJ, Rogers RM, Make BJ, Criner GJ, Cherniack RM, Patel SA, Chu F, Coxson HO, **Sharafkhaneh A**, Elliot M, Luketich JD, Hogg JC. Relationship Between Pathologic Characteristics Of Peripheral Airways And Outcome After Lung Volume Reduction Surgery In Severe Chronic Obstructive Pulmonary Disease. *Proceeding of American Thoracic Society* 2006;3(6):533-4.
53. Cully JA, Graham DP, Stanley MA, Ferguson CJ, **Sharafkhaneh A**, Soucek J, Kunik Me. Quality Of Life In Patients With Chronic Obstructive Pulmonary Disease And Comorbid Anxiety Or Depression. *Psychosomatics*. 2006; 47(4):312-9.
54. Williams OW, **Sharafkhaneh A**, Kim V, Dickey Bf, Evans Cm. Airway Mucus: From Production to Secretion. *American Journal of Respiratory Cell Molecular Biology*. 2006; 34(5):527-36.
55. **Sharafkhaneh A**, Giray N, Richardson P, Young T, Hirshkowitz M. Association of psychiatric disorders and sleep apnea in a large cohort. *Sleep*. 2005;28(11):1405-11.
56. Hirshkowitz M, **Sharafkhaneh A**. Clinical and Technologic Approaches to Sleep Evaluation. *Neurology Clinics* 2005; 23(4):991-1005
57. Hirshkowitz M, **Sharafkhaneh A**. The Physiology of Sleep. *Handbook of Neurophysiology*. 2005:3-20
58. Hirshkowitz M, **Sharafkhaneh A**. Positive Airway Pressure Therapy of OSA. *Seminars in Respiratory and Critical Care Medicine* 2005; 26(1):68-79
59. **Sharafkhaneh A**, Goodnight-White S, Officer Tm, Rodarte J, Boriek Am. Altered Thoracic Gas Compression Contributes to Spirometry Improvement with Lung Volume Reduction Surgery. *Thorax*. 2005; 60(4):288-92
60. Max Hirshkowitz, **Sharafkhaneh A**. On Measurement Consistency and Other Hobgoblins. *Sleep*. 2004; 27(5):847-8.
61. **Sharafkhaneh A**, Officer Tm, Goodnight-White S, Rodarte J, Boriek Am. Innovative Methodology. A Novel Method for Measuring Effects of Gas Compression On Expiratory Flow. *American Journal of Physiology*. 2004; 287(2):R479-84.
62. **Sharafkhaneh A**, Richardson P, Hirshkowitz H. Sleep Apnea in a High Risk Population: A Study Of Veterans Health Administration Beneficiaries. *Sep Med*. 2004; 5(4):345-50
63. **Sharafkhaneh A**, Baaklini W, Gorin Ab, Green Lk. Yield of Transbronchial Needle Aspiration (TBNA) In Diagnosis Of Mediastinal Lesions. *Chest*. 2003; 124(6):2131-5
64. **Sharafkhaneh A**, Hirshkowitz M. Effect of Contextual Factors on Self-Reported Sleepiness- A Preliminary Report. *Sleep Medicine* 2003 Jul; 4(4):327-31.
65. Hanania N, **Sharafkhaneh A**, Barber R, Dickey Bf. Pulmonary Perspective: Beta-Agonist Intrinsic Efficacy. *American Journal of Respiratory and Critical Care Medicine*. 2002 15; 165(10):1353-8

66. Hirshkowitz M, **Sharafkhaneh A**. Sleep Tools. Chest 119: 1303; 2001.
67. Baaklini W, Gorin A, Rinoso M, **Sharafkhaneh A**, Mannian P. Diagnostic Yield of Fiberoptic Bronchoscopy In The Evaluation Of Solitary Pulmonary Nodule. Chest 2000; 117: 1049-1054
68. Friedman Hs, Wattanasuwan N, **Sharafkhaneh A**, Win M, Mallipeddi D, Khan La, Dai CP. The Comparative Effects of Drive And Test Stimulus Intensity On Myocardial Excitability And Vulnerability. Pacing Clinics and Electrophysiology. 2000; 23:84-95
69. Friedman Hs, Rodney E, Sinha B, **Sharafkhaneh A**, Wattanasuwan N, Win M, Mallipeddi D, Sinha A, Hussain A, Dai CP. Verapamil Prolongs Atrial Fibrillation By Evoking An Intense Sympathetic Neurohumoral Effect. Journal Investig. Med. 1999; 47: 293-303
70. Friedman Hs, Sinha B, Tun A, Pasha R, **Sharafkhaneh A**, Bharadwaj A. Zones of Atrial Vulnerability: Relationships to Basic Cycle Length. Circulation 1996; 94:1456-1464

The following list of publications is part of several large studies. The studies included COPD Gene study, ECLIPSE Study and UPLIFT Study. COPD Gene is an ongoing NIH funded study that aims at identifying genetic risk factors for COPD. The ECLIPSE study is a very large longitudinal observational study funded by GSK. This study aims at identifying various COPD phenotypes and various disease courses. The UPLIFT study was a very large prospective randomized study that helped to evaluate course of COPD in a large cohort of COPD (6000 subjects with over 4 years of follow up). I played a major part in the studies in the capacity of site PI. . I am part of several subcommittees in the studies. I participate in biweekly or monthly teleconferences and yearly in person meeting. The meetings focus on design of the sub-studies, analysis of the data and publications. I was part of writing committee on several publications resulting from the studies (listed above). The following are the publications that I was not part of the writing committee but I am listed in PubMed search.

1. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agustí A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG; TESRA and ECLIPSE Investigators (**Sharafkhaneh A**). Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57.
2. Miller J, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, Macnee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators(**Sharafkhaneh A**). Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013 Sep;107(9):1376-84.

3. Agustí A, Edwards LD, Celli B, Macnee W, Calverley PM, Müllerova H, Lomas DA, Wouters E, Bakke P, Rennard S, Crim C, Miller BE, Coxson HO, Yates JC, Tal-Singer R, Vestbo J; ECLIPSE Investigators (**Sharafkhhaneh A**). Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. *Eur Respir J*. 2013 Sep;42(3):636-46.
4. Gietema HA, Edwards LD, Coxson HO, Bakke PS; ECLIPSE Investigators (**Sharafkhhaneh A**). Impact of emphysema and airway wall thickness on quality of life in smoking-related COPD. *Respir Med*. 2013 Aug;107(8)
5. Hersh CP, Washko GR, Estépar RS, Lutz S, Friedman PJ, Han MK, Hokanson JE, Judy PF, Lynch DA, Make BJ, Marchetti N, Newell JD Jr, Sciruba FC, Crapo JD, Silverman EK; COPDGene Investigators (**Sharafkhhaneh A**). Paired inspiratory-expiratory chest CT scans to assess for small airways disease in COPD. *Respir Res*. 2013 Apr 8;14:42.
6. Benzo R, Siemion W, Novotny P, Sternberg A, Kaplan RM, Ries A, Wise R, Martinez F, Utz J, Sciruba F; National Emphysema Treatment Trial Research Group (**Sharafkhhaneh A**). Factors to inform clinicians about the end of life in severe chronic obstructive pulmonary disease. *J Pain Symptom Manage*. 2013 Oct;46(4):491-499
7. Hansel NN, Washko GR, Foreman MG, Han MK, Hoffman EA, DeMeo DL, Barr RG, Van Beek EJ, Kazerooni EA, Wise RA, Brown RH, Black-Shinn J, Hokanson JE, Hanania NA, Make B, Silverman EK, Crapo JD, Dransfield MT; COPDGene Investigators (**Sharafkhhaneh A**). Racial differences in CT phenotypes in COPD. *COPD*. 2013 Feb;10(1):20-7.
8. Chandra D, Wise RA, Kulkarni HS, Benzo RP, Criner G, Make B, Slivka WA, Ries AL, Reilly JJ, Martinez FJ, Sciruba FC; NETT Research Group (**Sharafkhhaneh A**). Optimizing the 6-min walk test as a measure of exercise capacity in COPD. *Chest*. 2012 Dec;142(6):1545-52.
9. Kim DK, Cho MH, Hersh CP, Lomas DA, Miller BE, Kong X, Bakke P, Gulsvik A, Agustí A, Wouters E, Celli B, Coxson H, Vestbo J, MacNee W, Yates JC, Rennard S, Litonjua A, Qiu W, Beaty TH, Crapo JD, Riley JH, Tal-Singer R, Silverman EK; ECLIPSE, ICGN, and COPDGene Investigators (**Sharafkhhaneh A**). Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2012 Dec 15;186(12):1238-47.
10. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Marmar AJ, Regan E, Bailey WC, Martinez FJ, Westfall E, Beaty TH, Curran-Everett D, Curtis JL, Hokanson JE, Lynch DA, Make BJ, Crapo JD, Silverman EK, Bowler RP, Dransfield MT; COPDGene Investigators; ECLIPSE Study Investigators (**Sharafkhhaneh A**). Pulmonary arterial enlargement and acute exacerbations of COPD. *N Engl J Med*. 2012 Sep 6;367(10):913-21.
11. Kim V, Kretschman DM, Sternberg AL, DeCamp MM Jr, Criner GJ; National Emphysema Treatment Trial Research Group (**Sharafkhhaneh A**). Weight gain after lung reduction surgery is related to improved lung function and ventilatory efficiency. *Am J Respir Crit Care Med*. 2012 Dec 1;186(11):1109-16.

12. Zach JA, Newell JD Jr, Schroeder J, Murphy JR, Curran-Everett D, Hoffman EA, Westgate PM, Han MK, Silverman EK, Crapo JD, Lynch DA; COPDGene Investigators (**Sharafkhaneh A**). Quantitative computed tomography of the lungs and airways in healthy nonsmoking adults. *Invest Radiol*. 2012 Oct;47(10):596-602.
13. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators (**Sharafkhaneh A**). Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. *PLoS One*. 2012;7(5):e37483.
14. Martinez CH, Chen YH, Westgate PM, Liu LX, Murray S, Curtis JL, Make BJ, Kazerooni EA, Lynch DA, Marchetti N, Washko GR, Martinez FJ, Han MK; COPDGene Investigators (**Sharafkhaneh A**). Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. *Thorax*. 2012 May;67(5):399-406.
15. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, Himes BE, Sylvia JS, Klanderman BJ, Ziniti JP, Lange C, Litonjua AA, Sparrow D, Regan EA, Make BJ, Hokanson JE, Murray T, Hetmanski JB, Pillai SG, Kong X, Anderson WH, Tal-Singer R, Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PM, Celli B, Crim C, Rennard S, Wouters E, Bakke P, Gulsvik A, Crapo JD, Beaty TH, Silverman EK; ICGN Investigators; ECLIPSE Investigators; COPDGene Investigators (**Sharafkhaneh A**). A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. *Hum Mol Genet*. 2012 Feb 15;21(4):947-57.
16. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort (**Sharafkhaneh A**). *Respir Res*. 2011 Nov 4;12:146.
17. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI; ECLIPSE Investigators (**Sharafkhaneh A**). Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med*. 2011 Sep 29;365(13):1184-92.
18. Rambod M, Porszasz J, Make BJ, Crapo JD, Casaburi R; COPDGene Investigators (**Sharafkhaneh A**). Six-minute walk distance predictors, including CT scan measures, in the COPDGene cohort. *Chest*. 2012 Apr;141(4):867-75.
19. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo JD, Hersh CP; COPDGene Investigators (**Sharafkhaneh A**). The clinical features of the overlap between COPD and asthma. *Respir Res*. 2011 Sep 27;12:127.
20. Qiu W, Cho MH, Riley JH, Anderson WH, Singh D, Bakke P, Gulsvik A, Litonjua AA, Lomas DA, Crapo JD, Beaty TH, Celli BR, Rennard S, Tal-Singer R, Fox SM, Silverman EK, Hersh CP; ECLIPSE Investigators (**Sharafkhaneh A**). Genetics of spu-

tum gene expression in chronic obstructive pulmonary disease. PLoS One. 2011;6(9):e24395.

21. Come CE, Divo MJ, San José Estépar R, Sciurba FC, Criner GJ, Marchetti N, Scharf SM, Mosenifar Z, Make BJ, Keller CA, Minai OA, Martinez FJ, Han MK, Reilly JJ, Celli BR, Washko GR; NETT Research Group (**Sharafkhaneh A**). Lung deflation and oxygen pulse in COPD: results from the NETT randomized trial. *Respir Med*. 2012 Jan;106(1):109-19.
22. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ, Kim V, Bowler RP, Hanania NA, Anzueto AR, Make BJ, Hokanson JE, Crapo JD, Silverman EK, Martinez FJ, Washko GR; COPDGene Investigators (**Sharafkhaneh A**). Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. *Radiology*. 2011 Oct;261(1):274-82.
23. Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, Calverley PM, Tal-Singer R, Agusti A, Coxson HO, Lomas DA, MacNee W, Rennard S, Silverman EK, Crim CC, Yates J, Wouters EF; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators (**Sharafkhaneh A**). Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. *J Am Med Dir Assoc*. 2012 Mar;13(3):291-7.
24. Siedlinski M, Cho MH, Bakke P, Gulsvik A, Lomas DA, Anderson W, Kong X, Rennard SI, Beaty TH, Hokanson JE, Crapo JD, Silverman EK; COPDGene Investigators; ECLIPSE Investigators (**Sharafkhaneh A**). Genome-wide association study of smoking behaviours in patients with COPD. *Thorax*. 2011 Oct;66(10):894-902.
25. Castaldi PJ, Cho MH, Litonjua AA, Bakke P, Gulsvik A, Lomas DA, Anderson W, Beaty TH, Hokanson JE, Crapo JD, Laird N, Silverman EK; COPDGene and Eclipse Investigators (**Sharafkhaneh A**). The association of genome-wide significant spirometric loci with chronic obstructive pulmonary disease susceptibility. *Am J Respir Cell Mol Biol*. 2011 Dec;45(6):1147-53.
26. Foreman MG, Zhang L, Murphy J, Hansel NN, Make B, Hokanson JE, Washko G, Regan EA, Crapo JD, Silverman EK, DeMeo DL; COPDGene Investigators (**Sharafkhaneh A**). Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. *Am J Respir Crit Care Med*. 2011 Aug 15;184(4):414-20.
27. Crim C, Celli B, Edwards LD, Wouters E, Coxson HO, Tal-Singer R, Calverley PM; ECLIPSE investigators (**Sharafkhaneh A**). Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. *Respir Med*. 2011 Jul;105(7):1069-78.
28. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, Estépar RS, Lynch DA, Brehm JM, Andriole KP, Diaz AA, Khorasani R, D'Aco K, Sciurba FC, Silverman EK, Hatabu H, Rosas IO; COPDGene Investigators (**Sharafkhaneh A**). Lung volumes and emphysema in smokers with interstitial lung abnormalities. *N Engl J Med*. 2011 Mar 10;364(10):897-906.

29. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators (**Sharafkhaneh A**). Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med*. 2010 Sep 16;363(12):1128-38.
30. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators (**Sharafkhaneh A**). Characterisation of COPD heterogeneity in the ECLIPSE cohort. *Respir Res*. 2010 Sep 10;11:122.
31. Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, Lomas DA, Silverman EK; ECLIPSE and ICGN Investigators (**Sharafkhaneh A**). Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2010 Dec 15;182(12):1498-505.
32. Chandra D, Lipson DA, Hoffman EA, Hansen-Flaschen J, Scirba FC, Decamp MM, Reilly JJ, Washko GR; National Emphysema Treatment Trial Research Group (**Sharafkhaneh A**). Perfusion scintigraphy and patient selection for lung volume reduction surgery. *Am J Respir Crit Care Med*. 2010 Oct 1;182(7):937-46.
33. Benzo RP, Chang CC, Farrell MH, Kaplan R, Ries A, Martinez FJ, Wise R, Make B, Scirba F; NETT Research Group (**Sharafkhaneh A**). Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease. *Respiration*. 2010;80(1):10-8.
34. Giardino ND, Curtis JL, Andrei AC, Fan VS, Benditt JO, Lyubkin M, Naunheim K,
35. Criner G, Make B, Wise RA, Murray SK, Fishman AP, Scirba FC, Liberzon I, Martinez FJ; NETT Research Group (**Sharafkhaneh A**). Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study. *Respir Res*. 2010;11:29.
36. Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators (**Sharafkhaneh A**). Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. *Eur Respir J*. 2010;36(1):65-73.
37. Washko GR, Martinez FJ, Hoffman EA, Loring SH, Estépar RS, Diaz AA, Scirba
38. FC, Silverman EK, Han MK, Decamp M, Reilly JJ; National Emphysema Treatment Trial Research Group (**Sharafkhaneh A**). Physiological and computed tomographic predictors of outcome from lung volume reduction surgery. *Am J Respir Crit Care Med*. 2010 ;181(5):494-500.
39. Kumar S, **Sharafkhaneh A**, Edmonds J, Schultz R, Hopkins B. Treatment of VNS-induced laryngospasm with botulinum toxin. *Neurology*. 2009;73(21):1808-10.
40. Han MK, Wise R, Mumford J, Scirba F, Criner GJ, Curtis JL, Murray S, Sternberg A, Weinman G, Kazerooni E, Fishman AP, Make B, Hoffman EA, Mosenifar Z, Martinez FJ; NETT Research Group (**Sharafkhaneh A**). Prevalence and clinical correlates of bronchoreversibility in severe emphysema. *Eur Respir J*. 2010;35(5):1048-56.

41. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT Investigators (**Sharafkhaneh A**). Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. *Lancet*. 2009;374(9696):1171-8.

2) Books:

a. Books edited

1. Hanania N, Sharafkhaneh A (eds). *COPD: A Guide to Diagnosis and Clinical Management*, Respiratory Medicine Series, Humana Press, 2011
2. **Sharafkhaneh A.**, Kunik M., Yohannes A., Hanania N (eds). *Depression and Anxiety in Chronic Respiratory Diseases*, Humana Press, In-Preparation
3. **Sharafkhaneh A.**, Hirshkowitz M, Maskowitz A. *Principles and Practice of Fatigue Management to Improve Workplace Safety*. Humana Press, In-Preparation

b. Book Chapters:

4. Hirshkowitz H, Sharafkhaneh A. Diagnostic Assessment Methods. In Kryger MH (ed). *Atlas of Clinical Sleep Medicine*, 2nd edition, Philadelphia, PA: Saunders Elsevier, 2014: 270-394
5. Hanania H., Sharafkhaneh A. Chronic Obstructive Pulmonary Disease. In: Bope and Kellerman (eds) *Conn's Current Therapy*, Philadelphia, PA, 2013: 349-354
6. Hirshkowitz M, **Sharafkhaneh A**. Normal Sleep- Recording and Scoring Techniques. In: Chokroverty S, Montagna S (eds) *Handbook of Clinical Neurology Volume 98 Sleep Disorders*, part 1. Amsterdam: Netherlands, 2011; 29-43.
7. Hirshkowitz M, **Sharafkhaneh A**. Sleep and Genitourinary Systems- Physiology and Disorders. In: Chokroverty S, Montagna S (eds) *Handbook of Clinical Neurology Volume 98 Sleep Disorders*, part 1. Amsterdam: Netherlands, 2011; 355-362.
8. **Sharafkhaneh A**, Jamshidi M, Sharafkhaneh H, Hirshkowitz M. General management of issues in COPD: Sleep, Travel and Preoperative Management. In: Hanania N, Sharafkhaneh A (eds). *COPD: A Guide to Diagnosis and Clinical Management*, Respiratory Medicine Series, 2011, Chapter 16: 283-298
9. Bourbeau J., **Sharafkhaneh A.**, Adams S. Disease Management Programs in COPD. In: Hanania N, Sharafkhaneh A (eds). *COPD: A Guide to Diagnosis and Clinical Management*, Respiratory Medicine Series, 2011, Chapter 17: 299-312
10. Hirshkowitz M, **Sharafkhaneh A**. Diagnostic Assessment Methods. In: Kryger MH (ed) *Atlas of Clinical Sleep Medicine*, 1st edition. Philadelphia, PA: Saunders Elsevier, 2010; 261-282.

11. Hirshkowitz M, Seplowitz-Hafkin RG, **Sharafkhaneh A**. Sleep Disorders. In: Sadock BJ, Sadock VA (eds), Comprehensive Textbook of Psychiatry (8th Edition). Philadelphia: Lippincott, Williams & Wilkins, 2009; 2150-2177.
12. Hirshkowitz M, **Sharafkhaneh A**. Clinical Polysomnography and the Evolution of Recording and Scoring Technique. In: Chokroverty S (ed) Sleep Disorders Medicine (3rd Edition). Philadelphia, PA: Saunders Elsevier, 2009; 229-252.
13. Hirshkowitz M, Rose MW, **Sharafkhaneh A**. Neurotransmitters, neurochemistry, and the clinical pharmacology of sleep. In: Chokroverty S (ed) Sleep Disorders Medicine (3rd Edition). Philadelphia, PA: Saunders Elsevier, 2009; 67-79.
14. **Sharafkhaneh A**, Velamuri S, Badmeav V, Dickey F, Kurie J. Natural Agents in Chemoprevention of Lung Cancer. Third Edition, 2007
15. Hanania Na, **Sharafkhaneh A**. Lesson 22, Volume 20—Management of Lung Diseases in Elderly Patients, 2007
16. Hirshkowitz M, **Sharafkhaneh A**. The physiology of sleep. In: Guilleminault C (ed). Handbook of Clinical Neurophysiology- Clinical Neurophysiology of Sleep Disorders. Philadelphia: Elsevier, 2005; 3-20.

3. Guidelines:

1. VA/DOD COPD Guideline. 2007. COPD is among the major causes of mortality and health care use in the VHA beneficiaries. As such, the COPD guideline has been widely used and implemented in the VHA system. I currently co-chair a committee to update this guideline for VA and DOD.
2. VA Guideline for Use of Positive Airway Pressure Therapy, 2004. Obstructive sleep apnea (OSA) is a major medical problem in the VHA. The guideline for use of positive airway pressure therapy is vastly used in entire VHA for management of patients with OSA.
3. **CAQ Group**. Development and Validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire, 2005. I was part of a group scientist and researchers that developed the COPD Assessment Questionnaire (CAQ). CAQ has been used in various studies related to COPD.

4. Abstracts:

1. Qureshi H, Spiegelman A, Hanania H, **Sharfkhaneh A**. Total Mortality Decreased In Last Decade In Patients With Clinical Diagnosis Of COPD. Am J. Respir Crit Care Med 187; 2013:A2155.
2. Bird G., Casturi LR, Alapat P, **Sharafkhaneh A**, Sharafkhaneh S, Rao A. Sleep Habits Among High School Students Show a Significant Lack of Parental Limit Setting. SLEEP, Volume 35, 2012, A85

3. Cantu J, Abraham V, Velamuri K, Sharafkhaneh A. Clinical Implications of Undiagnosed Obstructive Sleep Apnea in Patients Undergoing Conscious Sedation for Bronchoscopy. *SLEEP*, Volume 35, 2012, A185
4. Sawhney V, Seethamraju H, Bourguet C, Hirshkowitz M, **Sharafkhaneh A**. Prevalence of Sleep Disorders in Lung Transplant Recipients. *SLEEP*, Volume 35, 2012, A298
5. Sawhney V, Baringer BC, Rossen JB, Majid H, Hirshkowitz M, **Sharafkhaneh A**. Prevalence of Sleep Disorders and Their Determinants in Patients with Chronic Pulmonary Disease. *SLEEP*, Volume 35, 2012, A298
6. Crothers KA, McGinnis K, Wongtrakool C, Lee P, Guidot DM, Soo Hoo G, Goetz M, Huang L, **Sharafkhaneh A**, Akgun KM, Shahrir A, Rimland D, Brown L. EXHALE, Predictors Of Elevated Oxidative Stress In Exhaled Breath Condensates Of HIV-Infected Patients. *Am J Respir Crit Care Med* 185;2012:A4059
7. Norman B, Pipavath S, Sigel K, Shahrir S, Akgun K, Kim J, Soo Hoo G, Brown L, Rimland D, Rodriguez-Barradas M, **Sharafkhaneh A**, Huang L, Crothers KA. Risk Factors for Incidentally Detected Lung Nodules On Chest CT Scan In HIV-Positive And HIV-Negative Veterans. *Am J Respir Crit Care Med* 185;2012:A4051
8. **Sharafkhaneh A**, Hanania NA, Colice GL, Donahue JD, Riedel A, Kurlander J, Altman PR. A Simple Rule To Identify COPD Patients Who May Need Treatment Re-Evaluation Based On Saba Use. *Am J Respir Crit Care Med* 185;2012:A6867
9. **Sharafkhaneh, A.**, J. Southard, M. Goldman, T. Uryniak, and U. J. Martin. Long-Term Effect of Budesonide/formoterol Pressurized Metered-Dose Inhaler On Exacerbations And Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease. *Am.J.Respir.Crit.Care Med.* 2011.183:A1599.
10. Southard, J. G., **A. Sharafkhaneh**, M. Goldman, T. Uryniak, and U. J. Martin. Long-Term Tolerability Of Budesonide/Formoterol Pressurized Metered-Dose Inhaler In Patients With Chronic Obstructive Pulmonary Disease And A History Of Exacerbations. *Am.J.Respir.Crit.Care Med.* 2011, 183:A1597.
11. Al shair, K., H. Mullerova, N. W. Locantore, N. A. Hanania, **A. Sharafkhaneh**, E. F. Wouters, S. I. Rennard, and J. Vestbo. Fatigue in COPD Is Significantly Associated With Exacerbations; Data From The Eclipse Cohort Study. *Am.J.Respir.Crit.Care Med.* 2011. 183:A3974.
12. Campo, M., S. Shahrir, K. Oursler, D. Rimland, G. Soo Hoo, S. Brown, M. Goetz, L. Huang, D. H. Au, M. Rodriguez-Barradas, **A. Sharafkhaneh**, K. M. Akgun, and K. Crothers. Respiratory Symptoms Are Associated With Decreased Performance On 6-Minute Walk Test Among HIV-Infected Patients. *Am.J.Respir.Crit.Care Med*2011.. 183:A6268.
13. **Sharafkhaneh, A.**, R. A. Wolf, S. Goodnight, B. J. Make, D. P. Tashkin, and N. A. Hanania.. Patients' Perceptions and Attitudes Towards the Use of Nebulized Therapy for Chronic Obstructive Pulmonary Disease. *Chest*, 2010, 138:479A.

14. **Sharafkhaneh, A.**, R. A. Wolf, S. Goodnight, N. A. Hanania, D. P. Tashkin, and B. J. Make. Caregivers' Perceptions and Attitudes Toward the Use of Nebulized Therapy for Chronic Obstructive Pulmonary Disease. *Chest*, 2010, 138:481A.
15. **Sharafkhaneh, A.**, H. Sharafkhaneh, and M. Hirshkowitz. In Patient Health Care Utilization Is Higher In Veterans With Sleep Apnea. *Am.J.Respir.Crit.Care Med.* 2010.181:A6547.
16. **Sharafkhaneh, A.**, H. Sharafkhaneh, and M. Hirshkowitz. 2010. Outpatient Health-care Utilization Is Higher in Veterans With Sleep Apnea. *Chest* 138:638A.
17. Quon, L., **A. Sharafkhaneh**, C. A. Velasco, M. A. Lopez, E. A. Hoffman, and A. M. Boriek. Rib Cage Displacements In Patients With Severe Chronic Obstructive Pulmonary Disease. *Am.J.Respir.Crit.Care Med.* 2010.181:A5981.
18. **Sharafkhaneh, A.**, B. F. Dickey, and N. A. Hanania. The Partial Expiratory Flow is More Sensitive Than FEV1 To bronchodilator Properties Of Inhaled Beta2-agonists With Different Intrinsic Efficacies. *Am.J.Respir.Crit.Care Med.* 2010.181:A5008.
19. Hanania, N. A., M. Foreman, **A. Sharafkhaneh**, R. A. Wise, L. Zhang, D. DeMeo, J. Schroeder, E. Regan, and B. J. Make. Characteristics of Elderly COPD Patients In The COPDGene(R) Cohort. *Am.J.Respir.Crit.Care Med.* 2010.181:A1563.
20. Hanania, N. A., **A. Sharafkhaneh**, H. X. Muellerova, M. L. Watkins, N. W. Locantore, J. Vestbo, and E. M. Wouters. Characteristics Associated with Depressive Symptoms (DS) in Patients with COPD. 2009.*Am.J.Respir.Crit.Care Med.* 179:A4046.
21. Lopez, M. A., **A. Sharafkhaneh**, C. Velasco, E. A. Hoffman, and A. M. Boriek. Does Midcostal Diaphragm Curvature Correlate with Severity of COPD? *Am.J.Respir.Crit.Care Med.* 2009.179:A4202.
22. Muth EH, Hamidi A, Hirshkowitz M, Dehgahn K, **Sharafkhaneh A.** WEIGHT CHANGE AFTER TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH POSITIVE AIRWAY PRESSURE. SLEEP, Volume 32, Abstract Supplement, 2009, A223
23. Hirshkowitz M, Sharafkhaneh H, Tang J, **Sharafkhaneh A.** CENTRAL AND OBSTRUCTIVE SLEEP RELATED BREATHING DISORDERS IN PATIENTS WITH SYSTOLIC CARDIAC DYSFUNCTION. SLEEP, Volume 30, Abstract Supplement, 2007, A32
24. CAQ Development Group. Development and Validation of A Patient-Based Measure of COPD Stability (Chest 2006)
25. Remzi Bag, Zimmerman J., **Sharafkhaneh A.**, Dickey BF, Hanania N. A Full Beta2-Agonist Is More Effective Than A Partial Agonist In Acute Severe Asthma. Chest 2005
26. Sharafkhaneh H, Hirshkowitz M, **Sharafkhaneh A.**, Bozkurt B. Endothelial Dependent Vascular Dilation Is Abnormal In Patients With Obstructive Sleep Apnea, SLEEP, Volume 28, Abstract Supplement, 2005, A210

27. Hirshkowitz M, **Sharafkhaneh A**, Cyclic Alternating Pattern (CAP) And Primary Insomnia. SLEEP, Volume 28, Abstract Supplement, 2005, A249
28. Hossein Sharafkhaneh, **Sharafkhaneh A.**, Hirshkowitz H. Atrial Overdrive Pacing In Patients with Obstructive Sleep Apnea. Chest, 2004
29. **Amir Sharafkhaneh**, Officer Tm, Rodarte Jr., Sharafkhaneh H., Boriek Am. Thoracic Gas Compression Modifies Effect Of Bronchodilator On Expiratory Flow. Chest 2004
30. Thomas Kaleekal, Guy E, **Sharafkhaneh A.** Expiratory Flow Limitations in Non-Obstructed Obese Patients. Chest 2004
31. **Amir Sharafkhaneh**, Dickey Bf, Hanania N. Maximal Partial Expiratory Flow Is More Sensitive Than Maximal Full Expiratory Flow & Fev1 In Determining Bronchodilator Response. Chest 2004
32. **Sharafkhaneh A**, Sharafkhaneh H, Bozkurt B, Hirshkowitz M, Prevalence Of Self-Reported Sleepiness In Patients With Cardiac Permanent Pacemaker. SLEEP, Volume 27, Abstract Supplement, 2004, A212
33. Hirshkowitz M, Raj R, **Sharafkhaneh A**, Improved Alertness in CPAP-treated Patients Not Meeting New Medicare Criteria for CPAP, SLEEP, Vol. 26, Abstract Supplement, 2003, A215
34. **Sharafkhaneh A**, Richardson P, Hirshkowitz M, Sleep Related Breathing Disorders in Veteran Beneficiaries. SLEEP, Vol. 26, Abstract Supplement, 2003, A236
35. **Sharafkhaneh A**, Officer T., Goodnight-White S., Rodarte J. Effect Of Gas Compression On Flow In Severe COPD. American Thoracic Society 2002
36. Goodnight-White S, Jones JW, Baaklini WB, Soltero E, Smithwick P, **Sharafkhaneh A**, Officer T, Reinoso M, Manian P, Miller C, Rodarte Jr. Lung Volume Reduction Surgery (LVRS) In Patients with Severe Emphysema: 1 Year Follow Up. American Thoracic Society 2001
37. Goodnight-White Sg, Jones Jw, Baaklini Wb, **Sharafkhaneh A**, Soltero E, Smithwick P, Officer T, Reinoso Ma, Manian Pm, Miller C, Rodarte Jr. Prospective Randomized, Controlled Trial Comparing Bilateral Lung Volume Reduction Surgery (LVRS) To Medical Therapy Alone In Patients With Severe Emphysema. Chest 2000
38. **Sharafkhaneh A**, Ece F, Ece T, Keus L, Morice Rc. A Retrospective Study Comparing Expandable Stent Placement In Operating Room Versus Bronchoscopy Suite, and Endotracheal Versus Nasal Routes. Chest 2000
39. **Sharafkhaneh A**, Baaklini W, Hirshkowitz M. Relative Importance Of Position, Location, And Activity Interest Level On Self-Reported Sleepiness. APSS 2000
40. **Sharafkhaneh A**, Green L, Baaklini W, Gorin A. Yield of Transtracheal Fine Needle Aspiration in Mediastinal Lesions. American Thoracic Society 2000)

41. **Sharafkhaneh A.**, Baaklini W., Hirshkowitz M. Convergent and Divergent Validation of Self-Reported Sleepiness Questionnaires. Southern Sleep Society Meeting 2000
42. Baaklini W, Gorin A, Rinoso M, **Sharafkhaneh A**, Mannian P. Diagnostic Yield Of Fiberoptic Bronchoscopy In The Evaluation Of Solitary Pulmonary Nodule. Chest 1999
43. Baaklini W, **Sharafkhaneh A**, Hirshkowitz M. Predicting CPAP Adherence in Patients With Sleep-Disordered Breathing. Southern Sleep Society Meeting 1999
44. Friedman Hs, Sinha B, **Sharafkhaneh A**, Dai C, Wattanasuwan N, Saxena A, Reddy M. Verapamil Enhances Atrial Fibrillation By Evoking An Intense Sympathoadrenal Effect. (J. Investig. Med. 1996; 44: A407-A407)
45. Friedman Hs, Sinha B, Tun A, **Sharafkhaneh A**, Wattanasuwan N, Dai C. Excitability As A Determinant Of Atrial Fibrillation Inducibility. (J. Investig. Med. 1996; 44: A210-A210)
46. Friedman Hs, Sinha B, **Sharafkhaneh A**, Pasha R, Bharadwaj A, Tun A. Zones Of Atrial Vulnerability Relationships To Basic Cycle Length. (J. Investig. Med. 1996; 44: A210-A210)
47. Friedman Hs, Sinha B, Tun A, Pasha R, **Sharafkhaneh A**, Bharadwaj A. Effect Of Drive Intensity On Atrial Excitability And Vulnerability. 18th Annual Scientific Session Of North American Society Of Pacing And Electro-Physiology, 1996

III. TEACHING INFORMATION

A. Didactic Course Work

1. Courses taught at BCM in Primary Department

Medicine Resident Training

Internal Medicine Noon Lecture Series, Pulmonary Medicine (1 Lecture/Year X 3 Hospitals), 2003- Present (Baylor College of Medicine)

Ambulatory Care Medicine Lecture Series, MED VAMC (2 Lectures/Year), 2004- 2007

Morbidity and Mortality Conference, Medicine Service, MED VAMC (1-2 Conferences/Year), 2004-2008

Critical Care Medicine, MED VAMC (4 Lectures/Month, 1-2 Months per Year), 2000-Present

Pulmonary and Critical Care Fellow Training

Pulmonary and Critical Care Fellowship Core Curriculum Series (2 Lectures per Year), Baylor College Of Medicine, 2001- Present

Pulmonary Fellow Respiratory Physiology Course (2 Lectures per Year), 2003-Present

Pulmonary Section Journal Club (2 per Year), 1998- Present

Pulmonary Research Conference (2 per Year), 1998- Present

Pulmonary Medicine, MED VAMC (1-2 Lectures/Week, 2 Months per Year), 2000- Present

Critical Care Medicine, MED VAMC (4 Lectures/Month, 1-2 Months per Year), 2000-Present

Sleep Fellow Training

Sleep Fellowship Curriculum, Baylor College of Medicine (12 Lectures per Year), 2000-Present. This is a comprehensive curriculum for training of sleep fellows in our ACGME accredited program at Baylor College of Medicine

Interpretation of Polysomnogram for Sleep Fellows (10 Hours/Week), 2001- Present

2. Courses taught at BCM external to Primary Department

Medical Student Training

Fall II, Respiratory Module, 2nd Year Medical Students (2 Lectures/Year), 1998-2000

Core Clerkship Lecture Series, 3rd Year Medical Students (2 Lectures/Year), 2004- 2012

Allied/Public Health Training

Allied Health Physiology Course, Respiratory Physiology (2 Hours/Course), 2004- Present

Sleep Technician Training, the Methodist Hospital Diagnostic Sleep Laboratory Technicians (3 Hours/Month), 2001- 2005

MED VAMC Pulmonary Function Respiratory Technician (1 Hour/Month), 2002- Present

Graduate Students Training

Physiology Course, Respiratory Physiology (1 Hours/Course), 2006- Present

Physiology Course, Renal Physiology (2 Hours/Course), 2006- Present

3. Courses taught at other institutions while at BCM

None

B. Curriculum Development Work

I, in collaborations with my colleagues, developed the curriculum for the ACGME sleep medicine fellowship training at Baylor College of Medicine. This curriculum was developed to meet all the requirements of the ACGME.

I also contributed significantly to development of sleep medicine fellowship curriculum for an international sleep medicine fellowship program in the Middle East. This fellowship is one of the first in the region.

C. Non-didactic teaching while at BCM

Clinical Fellow Training

Pulmonary In-Patient Consult Service, Bedside Teaching and Training in Pulmonary Procedures (12 Hours/Week, 1-2 Months per Year), 2000-Present

Pulmonary Out-Patient Consult Clinic, MED VAMC (4 Hours/Week, 12 Months/Year)

Critical Care Service, Bedside Teaching and Training in Critical Care Procedures (12 Hours/Week, 1-3 Months per Year), 2000-Present

ACGME accredited Pulmonary and Critical care Medicine Fellows

Hammad Qureshi

Juan Iribarren

Kapil Rangavajhala

Madhu Nair

Benjamin Blow
Philip T. Ong
Supriya Singh
Leonard Chow
Joseph L. Thachuthara-George
Kathrine Kintner
Ahmad Goodarzi
Lakshmi Mudambi
Lakshmi Iyer
Enrique Ortiz-Diaz
Kiran Nair
Christopher Howard

Sleep Fellow Training

Sleep Medicine Clinic, MED VAMC (8 Hours/Week, 12 Months/Year) **The trainees rotated for period of 6-12 months in the sleep laboratory and were trained in various aspects of sleep medicine.**

a) ACGME accredited Sleep Medicine Fellows

Beverly John
Diane Long
Amie Patel
Marco De La Santos
Jose Melendez
Suprya Singh
Walter Castro
Hanul Bhandari
Vishal Sawhany
Garrett Bird
Jose Cantue
Adam Foreman
Amarbir Mattewal
Sean Hesselbacher
Semya Ahmed
JB Rosen
Anandi Murugan
Lubna javed
Hashir Majid
Binal Kancherla
Summet Kumar
John Turner
Amie Stringfellow
Gnananandh Jayaraman
Ragu Reddy
Jennifer Chen

b) Non-ACGME Sleep Medicine Training (2000-2007)

James Ludwick
Mary Rose
Rabih Loutfi
Salah Lababidy
Sivagini Ganesh

Babith Manikdiyil
Tim Connolly
Rubina Kerawala
Tilottama Majumdar
Istvan Wollak
Rami El-Wali
Ed Ortiz
Phillip Alapat
Charlie Lan
Minh Tran
Osman Malik
S.L. Narayanan
Nizar Suleman
Thomas Kaleekal
Lara Bashoura
Nabeel Hamzeh
Suryakanta Velamuri

Research Mentoring

I have been extensively involved in mentoring many trainees (within Baylor and other Houston higher education insititutes) in design and conduct of the reseach studies, data analysis, and preparation of posters and manuscripts in last 13 years at Baylor. The stud-ies vary from randomized clinical trials to chart review studies and large database studies.

a) Resident Trainees

Leonard Chow
Hilma Holms
Arifin Alam
Manoj Mammon
Elizabeth Muth
Amik Sodh

b) Graduate & Allied Health Student Trainees

Christina Guijarro
Jennifer Guijarro
Kevin Main
Anu Anand
Bridget Baringer
M. Katie Tieman
Balamurugan Anaugur Ganesam (UT-School of Public Health)
Todd Officer
Parviz Kheirkhah (University of Houston)

c) Undergraduate Student Trainees

Paul Gatiback
Maribel Barin

d) Fellow Trainees

Madu Nair
Lakshmy Ayyer

Lakshmy Mudambi
Joseph Thachuthara-George
Kasra Dehghan
Myank Arora
Hanan Abdel-Monem
Tarak Aldamad
Lara Bashoura
Thomas Kaleekal
Minh Tran
Linda Mughrabi

4. Pre-Medical/Medical Student Training

Clinical Preceptor, Baylor College of Medicine, (2-4 Hours/Week, 4 Months/Year), 2004-2009

5. Clinical Resident Training

Pulmonary Consult Service, Bedside Teaching (5 Hours/Week, 1-2Months per Year), 2000-2004

Critical Care Service, Bedside Teaching (12 Hours/Week, 1-2 Months per Year), 2000-Present

D. Lectures (include location, title of presentation, date)

1. International

1. "Insomnia: An Update" Erbil Society of Neurologists, Erbil, Iraq, July 2013
2. "You Will Lose Your Heart If You Stop Dreaming" Erbil Cardiovascular Society, Erbil, Iraq, July 2013
3. "Sleep Disorder: Prevalence, Diagnosis & Management" 14th National Congress on cardiovascular Update, , Niroo Institute Conference center, Tehran, Iran, September, 2012
4. "Diagnosis & Management of PTE in cardiac patients" 14th National Congress on cardiovascular Update, Niroo Institute Conference center, Tehran, Iran September, 2012
5. "You will lose your heart if stop dreaming: Obstructive Sleep Apnea and Cardiovascular disorders", Hamad Hospital, Weil-Cornel University, Doha, Qatar, September, 2012
6. "Sleep Disorders: An Update" Tabriz University of Medical Sciences, Tabriz, Iran, Feb 2011.
7. "Home Sleep Testing" 5th National Congress on Sleep Disorders, Tehran, Iran, May, 2011
8. "Movements in Sleep: Scoring & Interpretation." National Research Institute of Tuberculosis & Lung disease (NRITLD), Kish, Iran, Feb, 2011

9. "Interpretation: Sleep Study-Adults" National Research Institute of Tuberculosis & Lung disease (NRITLD), Kish, Iran, Feb, 2011
10. "Simple Sleep Apnea Case-Adults" National Research Institute of Tuberculosis & Lung disease (NRITLD), Kish, Iran, Feb, 2011
11. "Invited Adult Lecture: Narcolepsy" National Research Institute of Tuberculosis & Lung disease (NRITLD), Kish, Iran, Feb, 2011
12. "Invited Adult Lecture: Update on Obesity Hypoventilation" National Research Institute of Tuberculosis & Lung disease (NRITLD), Kish, Iran, Feb, 2011
13. "Complex Sleep Apnea Case-Adults" National Research Institute of Tuberculosis & Lung disease (NRITLD), Kish, Iran, Feb, 2011
14. "COPD Exacerbations: Can we prevent them?" The 4th International Congress on Pulmonary Diseases, Intensive Care And Tuberculosis, Tehran, Iran, October 2009
15. "Sleep Related Breathing Disorders: Epidemiology and Diagnosis" The 4th International Congress on Pulmonary Diseases, Intensive Care And Tuberculosis, Tehran, Iran, October 2009
16. "Respiratory Physiology during wakefulness and sleep" The 4th International Congress on Pulmonary Diseases, Intensive Care And Tuberculosis, Tehran, Iran, October 2009
17. "Insomnia: Diagnosis and Treatment" The 4th International Congress on Pulmonary Diseases, Intensive Care And Tuberculosis, Tehran, Iran, October 2009
18. "Weight and sleep Disordered Breathing and CPAP therapy" The 4th International Congress on Pulmonary Diseases, Intensive Care And Tuberculosis, Tehran, Iran, October 2009
19. "Case Presentation: Polysomnography" The 4th International Congress on Pulmonary Diseases, Intensive Care And Tuberculosis, Tehran, Iran, October 2009
20. "Case Presentation: Sleep in COPD" The 4th International Congress on Pulmonary Diseases, Intensive Care And Tuberculosis, Tehran, Iran, October 2009
21. "Sleep Disorders and Workplace Safety" IV International Medical Congress of PEMEX in Mexico, June 2008
22. "Heart, Cytokines and OSA" A Year in Review Presentation at World Association Of Sleep Medicine (WASM), Berlin, October 2005

2. National

1. "COPD exacerbations" American College of Chest Physician Meeting, October 2007
2. "Thoracic Gas Compression" American College of Chest Physician Airway Physiology Network Meeting, October 2007

3. "Predictive models of COPD exacerbations" Puerto Rico VA Medical Center, September 2007
4. "Thoracic Gas Compression" First Young Investigator Conference, October 2004
5. "Obstructive Sleep Apnea and Heart Failure: The Missing Link" Sunrise Seminars, American Thoracic Society International Meeting, May 2004
6. "Outcomes and Benefits of Pap Therapy" National P&SAS and Pulmonary Service Conference, May 2003.

3. Regional

1. "COPD Exacerbations: An Update" Regional COPD Foundation Conference, August 2012
2. "COPD Exacerbations: An Update" 63rd Annual KOPPA Conference, August 2010
3. "Cardiac Arrhythmias in Sleep Apnea" Southern Sleep Society Meeting, April 2004

4. Local

1. "Techniques in Managing Comorbid Obesity in OSA" A Presentation at Southern Sleep Society 2008 meeting
2. "Obstructive Sleep Apnea" A Presentation at Arab-American Society meeting on March 2008
3. "Health Care Utilization in Obstructive Sleep Apnea" A Grand Round Presentation at MED VAMC November 2007
4. "Update in COPD" A Grand Round Presentation at Baylor College of Medicine October 2007
5. "Cardiac Arrhythmias in Obstructive Sleep Apnea" A CEU Course For Respiratory Therapist, MED VAMC October 2005
6. "You Will Lose Your Heart If Stop Dreaming" Med VAMC Grand Rounds, March 2005
7. "Up-To-Date In Management of Obstructive Lung Disease" Beaumont VA Clinic, March 2005
8. "Sleep Related Breathing Disorders for Primary Health Care Providers" VAMC Prime Care Clinic, March 2005
9. "COPD: A New Look at an Old Disease" Conroe Regional Medical Center Family Practice Residency Noon Conference, February 2005
10. "Intriguing New Ideas in the Pathophysiology and Management of COPD" Texas Gulf

Coast Physician Assistant Association, February 2004

11. "Lung Mechanic Data from Lung Volume Reduction Surgery" The Pulmonary Research Conference Series, Department Of Pulmonary Medicine, MD Anderson Cancer Center, February 2005
12. "Role of Mucins in Acute Exacerbations of COPD" Baylor College of Medicine Pulmonary Research Conference, February 2005
13. "Update On COPD" The Memorial Southwest Respiratory Department, December 2004
14. "Frontline Management of COPD" UTMB Primary Care Clinic, November 2004
15. "Atrial Overdrive Pacing In Patients with Obstructive Sleep Apnea" Graduate Student Symposium, the Graduate School of Biomedical Sciences, Baylor College of Medicine, October 2004
16. "COPD for Respiratory Therapist" Memorial Southwest Respiratory Therapy Department, October 2005
17. "Cardiac Pacing In Sleep Apnea" Pulmonary Section Research Conference, Baylor College Of Medicine, September 2004
18. "COPD: An Update for Primary Care Physicians" Med VAMC Prime Care Clinic, July 2004
19. "A Rational Approach to Management of COPD" Lake Charles Memorial; Hospital CME Program for Family Practice Faculty and Residents, June 2004
20. "Chronic Obstructive Pulmonary Disease" Spring Branch Medical Center CME Program of Physicians, June 2004
21. "COPD for Allied Health Care Provider" Texas Society of Pharmacist, April 2004
22. "COPD for Respiratory Therapist: Texas Society for Respiratory Care South Region Spring Seminar, May 2004
23. "Lung Physiology for Respiratory Therapists" Texas Society for Respiratory Care South Region Spring Seminar, May 2003
24. "Intermittent Hypoxia" Pulmonary and Critical Care Research Conference, Baylor College of Medicine, Houston, Texas, September 2002
25. "Ventilatory Support in COPD", Houston VA Medical Center Respiratory Therapy Symposium, Houston, TX, October 2001.

26. "Sleep Related Breathing Disorders" Houston VA Medicine Grand Round, Houston, TX, April 2001.
27. "Airway Inflammation in COPD", Pulmonary and Critical Care Research Conference, Baylor College of Medicine, Houston, Texas, February 2001

E. Visiting Professorships:

None

IV. MEDICAL AND SERVICE INFORMATION

A. Patient Care Responsibilities at BCM and/or its Affiliated Institutions

1. Staff Physician, Sleep Disorders and Research Center: 12 Months
2. VA MICU attending, 1-2 Months per Year
3. VA Pulmonary Consult attending, 1-2 Months per Year
4. VA Pulmonary Clinic, ½ Day/Week, 12 Months per Year
5. VA Bronchoscopy Services attending , 1-2 Months per Year
6. Sleep Disorders Clinic, 2 Half a Day Clinic Supervising sleep medicine fellows, 12 Months

B. Clinical Laboratory Responsibilities at BCM and/or its Affiliated Institutions

2003-Present Medical Director, Sleep Disorders and Research Center, MEDVAMC

2000-Present Staff Physician, Michael E. DeBakey VA Medical Center (MEDVAMC)

2000-2005 Medical Director, Pulmonary Function Laboratory, MEDVAMC

2005-007 Medical Director, Home Oxygen Clinic, MEDVAMC

C. National Education or Voluntary Health Organization Participation:

D. Administrative Assignments at BCM:

1. Department Administration, Committees, etc.:

None

2. College Administration, Committees, etc.:

2010-Present Alternate Member, R&D Committee at the MEDVAMC

2002-2006 Member, IRB at Baylor College of Medicine

2003-2006 Member, Medical School Interview Committee

E. Other Pertinent Information not given above:

1. Chair, Fellowship Curriculum Committee, Sleep Medicine Fellowship at Baylor College of Medicine

2. Co-Chair, Fellows Research Oversight Committee, Sleep Medicine Fellowship at Baylor College of Medicine
3. Co-Chair, Fellowship Steering Committee, Sleep Medicine Fellowship at Baylor College of Medicine
4. Member, Fellows Research Oversight Committee, Pulmonary and Critical Care